Summary of evidence and Expert Committee recommendations
Comments on budesonide as listed in the 2nd edition of the EMLc were received from Cécile Mace, Asthma Drug Facility Coordinator, Quality Assurance Pharmacist, International Union Against Tuberculosis and Lung Disease.
The Committee noted that Miss Mace had correctly pointed out the errors in the description of budesonide metered dose inhlaers with reference to strengths and the salt “dipropionate”.
The Committee approved the corrected version as: budesonide Inhalation (aerosol): 100 micrograms per dose and 200 micrograms per dose.
The Committee noted the confusion arising from this error as to whether budesonide or beclometasone is the corticosteroid included in the EMLc, and confirmed that budesonide was chosen as it is more widely available.